| Key Points | Details |
|---|---|
| Mechanism | Clarithromycin inhibits CYP3A4, the liver enzyme that metabolizes certain statins (simvastatin, atorvastatin, lovastatin). |
| Effect | Inhibition leads to increased statin blood levels, raising the risk of muscle toxicity. |
| Risks | Muscle pain (myalgia), weakness (myopathy), severe muscle breakdown (rhabdomyolysis), and acute kidney injury. |
| High-Risk Statins | Avoid combining clarithromycin with simvastatin and lovastatin; use atorvastatin cautiously. |
| Safer Alternatives | Pravastatin, rosuvastatin, and fluvastatin are less dependent on CYP3A4 and safer options. |
| Clinical Guidance | Review medications, consider alternative antibiotics (e.g., azithromycin), monitor for muscle symptoms, and educate patients to report muscle pain or dark urine. |
Summary
Clarithromycin significantly increases plasma levels of certain statins by inhibiting CYP3A4, risking serious muscle toxicity. Avoid high-risk statins or choose safer alternatives, monitor patients closely, and educate them to ensure safe treatment.
MBH/PS